Skip to main content
Erschienen in:

Open Access 30.09.2023

Characterization of durability and reconnection patterns at time of repeat ablation after single-shot pulsed field pulmonary vein isolation

verfasst von: Martin H. Ruwald, Martin Haugdal, Rene Worck, Arne Johannessen, Morten Lock Hansen, Samuel K. Sørensen, Jim Hansen

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 2/2024

Abstract

Background

Pulsed field ablation (PFA) is a novel method of cardiac ablation where there is insufficient knowledge on the durability and reconnection patterns after pulmonary vein isolation (PVI). The aim of this study was to characterize the electrophysiological findings at time of repeat procedure in real-world atrial fibrillation (AF) patients.

Methods

Patients who underwent a repeat procedure (n=26) for symptomatic recurrent arrhythmias after index first-time treatment with single-shot PFA PVI (n=266) from July 2021 to June 2023 were investigated with 3D high-density mapping and ad-hoc re-ablation by radiofrequency or focal PFA.

Results

Index indication for PVI was persistent AF in 17 (65%) patients. The mean time to repeat procedure was 292 ± 119 days. Of the 26 patients (104 veins), complete durable PVI was observed in 11/26 (42%) with a durable vein isolation rate of 72/104 (69%). Two patients (8%) had all four veins reconnected. The posterior wall was durably isolated in 4/5 (80%) of the cases. The predominant arrhythmia mechanism was AF in 17/26 (65%) patients and regular atrial tachycardia (AT) in 9/26 (35%). Reconnection was observed 9/26 (35%) in right superior, 11/26 (42%) in right inferior, 7/26 (27%) in left superior, 5/26 (19%) in left inferior, p=0.31 between veins. The gaps were significantly clustered in the right-sided anterior carina compared to other regions (P=0.009).

Conclusions

Durable PVI was observed in less than half of the patients at time of repeat procedure. No significant difference in PV reconnection pattern was observed, but the gap location was preferentially located at the anterior aspects of the right-sided PVs. Predominant recurrence was AF. More data is needed to establish lesion formation and durability and AT circuits after PFA.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

1 Introduction

Pulmonary vein isolation (PVI) is the hallmark of invasive treatment for atrial fibrillation (AF). Thermal energy sources mainly used for PVI such as radiofrequency (RFA) and cryo-balloon ablation has shown moderate durability with frequent reconnection of the veins limiting beneficial clinical outcomes [1]. Irreversible electroporation of the cardiac myocytes by pulsed field ablation (PFA) has emerged as a novel non-thermal energy source to create sufficiently deep lesions suggesting a good lesion durability without any apparent extracardiac damage [24]. Early clinical studies showed high 3-month durability in scheduled remapping studies [5], and the safety and clinical efficacy of single-shot PFA has now been documented in larger datasets [513]. Still, however, the clinical efficacy seems only comparable to, and not superior to, the ablations performed with traditional thermal energy sources and randomized trials are eagerly awaited on this matter.
Recently, the first report was published of clinically indicated repeat procedures after a fluoroscopy-based single-shot PFA with the multispline catheter from the Farapulse system. This documented a low pulmonary vein (PV) reconnection rate (9%) and a relative high predominance of macro re-entry atrial tachycardias (AT) potentially using a narrow zone of viable myocardium between PVI lesions on the posterior left atrial wall (LAPW) [14]. With the PFA technology rapidly spreading and reaching worldwide numbers of ablated patients beyond 10,000, there is a continuous need to report industry-independent experiences including data on durability and reconnection patterns in real-life AF patients treated with the PFA systems.

2 Methods

The study was a prospective inclusion of an all-comer paroxysmal or persistent AF patient cohort. Patients were referred for first-time PVI as either first-line treatment or if intolerant to, refractory to, or unwilling to take class I or III antiarrhythmic drugs (AAD). Inclusion was based in a single high-volume referral center from July 7, 2021 to March 15, 2023 and latest follow-up for repeat procedure data on June 15, 2023 to allow for the possibility of repeat procedure by a minimum of 3 months follow-up of all patients.

2.1 Index PFA procedure

The index single-shot PFA procedure was done as described previously [10]. In short, patients were under general anesthesia and intubated and had standard vein punctures and access to the left atrium (LA). The multispline-electrode catheter (Farawave, Farapulse, Boston Scientific) was used for the PVI single-shot protocol used in our facility which was a fluoroscopy-based approach with computed tomography overlay of the LA for visual guidance. Intracardiac echocardiography was not used. PFA applications were delivered as two pairs in catheter “basket” formation and two pairs in “flower” formation—all pairs with an approximately 30–45° rotation of the spline orientation for a total of eight applications per vein. The applications were given unsynchronized to the ECG R-waves and as biphasic waveform using 2.0 kiloV amplitude. Confirmation of the PVI after single-shot protocol applications was done with the multispline catheter in a basket position by verification of entry and exit block to the vein. Additional PFA applications were added at the operator’s discretion and noted. Until July 1, 2022, a confirmatory Carto3 (Biosense Webster, Irvine, CA, USA) high-density (HD) 3D map of the LA was created after the PVI with fast anatomical mapping and bipolar voltage amplitude map using a pentaspline multielectrode Pentaray catheter (Biosense Webster) and additional PFA applications were performed and noted hereafter at the operator’s discretion as previously described [15].

2.2 Repeat procedure protocol

For the repeat procedures, HD or ultra-high-density (UHDx) bipolar voltage amplitude mapping of the LA was done as described above with penta- or octaspline (Pentaray or Octaray (Biosense Webster)) multielectrode catheters during proximal coronary sinus atrial pacing. The color display range of the bipolar voltage map was set to 0.2 to 0.5 mV to visualize gaps, zones of healthy tissue, and low voltage areas. Qualitative assessment of isolation, voltage, and scars was made along with formal testing of entry and exit blocks to the veins. Thereafter, attempted induction of trigger activity or AT with isoprenaline infusion to a heart rate> 100 bpm and atrial burst pacing was performed. ATs were mapped accordingly using local activation time maps and coherence conduction vectors to establish critical isthmuses and circuits with supplementary entrainment mapping if needed, as per clinical standard, and described earlier [10, 16, 17]. Ad-hoc ablation based on the above findings was performed with RFA through steerable sheaths with irrigated SmartTouch surround flow catheters (Biosense Webster) adhering best possible to the CLOSE protocol in terms of interlesion distance and ablation index [18] or by focal PFA utilizing the Galvanize EP (Galvanize EP) system through SmartTouch catheters (Biosense Webster) as described previously [19]. Choice of focal PFA, instead of RFA, was based on the availability of general anesthesia. Gap identification and location determination was based on the operator description; typically, a combination of local activation time map interpretation and timing and voltage of the intracardiac electrograms in the PV and the site of successful re-isolation or significant change in PV electrical pattern was used [1, 20]. Following ablations, either a confirmatory detailed UHDx bipolar voltage amplitude 3D map of the ablation line(s) in LA or right atrium was performed with the multielectrode catheter using proximal CS atrial pacing or created lines of block were tested for dormant conduction with adenosine or bidirectional block was confirmed after a 20-min waiting time. Supplementary CS atrial paced local activation time maps with evaluation over ablation lines could be applied in cases of isthmus block if deemed of relevance. Follow-up of complications up to 14 days after the procedure was available through chart review. This research study was conducted retrospectively from data obtained for clinical purposes utilizing anonymized data approved by Herlev-Gentofte University Hospital Institutional Review Board (Case Number:22035743).

2.3 Statistical analysis

For continuous variables the mean ± SD or median ± ÍQR were used as appropriate. For categorical values, the number and percentages were used. Comparisons of proportions were by chi-square tests or Fisher’s exact test as appropriate. Test of significance were 2-sided with p≤0.05 considered statistically significant.

3 Results

A total of 266 patients were treated with initial (index) first-time treatment with single-shot PFA PVI for AF all with more than 3 months of available follow-up. Of these, 26 (10%) came for a clinically indicated repeat procedure because of significant arrhythmia recurrences. At the index procedure, patients were on average 65 ± 10 years of age and 17 (65%) had persistent AF and 11 (42%) were male (Table 1). The mean time from first procedure to documented arrhythmia recurrence (excluding recurrences in a 90-day blanking period) was 179 ± 75 days and the mean time to repeat procedure was 292 ± 119 days. In the index procedure, a total of 11 patients (42%) had supplementary PFA applications to the PVs (more than 8 applications per vein protocol) and 15 patients (58%) were mapped with supplementary confirmatory 3D HD bipolar voltage maps after the PVI.
Table 1
Baseline characteristics at index procedure
 
n=26
Age, years
65 ±10
  EHRA class
2.5 ±0.6
  NYHA class
1.6 ±0.6
  Male sex, n (%)
11 (42)
  BMI, kg/m2
26 ±4
Type of AF
  Paroxysmal, n (%)
9 (35)
  Persistent, n (%)
17 (65)
  Coronary artery disease, n (%)
0
  Diabetes, n (%)
3 (12)
  Hypertension, n (%)
7 (27)
  Heart failure, n (%)
8 (31)
  Previous stroke, n (%)
1 (4)
  CHADSVASc score
2.1 ±1.4
  Left ventricular ejection fraction, %
51 ±11
  Left atrium diameter, mm
42 ±8
  Left atrium volume index, ml/m2
45 ±9
  Beta-blockers, n (%)
19 (73)
  Amiodarone, n (%)
2 (8)
  Direct oral anticoagulant, n (%)
25 (96)
Index procedure characteristics
  Single-shot PVI by protocol PFA applications (8 per vein only) at index procedure, n (%)
15 (58)
  HD mapping post-PVI at index procedure, n (%)
15 (58)
Values are in mean ±SD. AF atrial fibrillation, BMI body mass index, EHRA European Heart Rhythm Association, NYHA New York Heart Association, HD high density, PVI pulmonary vein isolation, PFA pulsed field ablation

3.1 Repeat procedural data and ablation strategy

The mean repeat procedure time was 114 ± 27 min, fluoroscopy time was 6 ± 3 min, and 9449 ± 7784 mapping points encompassed the first uHDx maps (Table 2). After interpretation of maps and attempts of tachycardia induction, the planned ablation strategy was re-isolation of PVs only in 7/26 (23%), LAPW isolation (LAPWi) only in 5/26 (19%), and combination of PV re-isolation with additional LAPWi in 3/26 (12%). The remaining strategies were combinations of PV re-isolation, LAPWi, cavotricuspidal isthmus block, anterior mitral isthmus block, and ablation of focal atrial tachycardias in 11/26 (42%). A total of 6/26 (23%) cases were treated with focal PFA.
Table 2
Procedural data repeat procedure
Procedural characteristics
Total
  General anesthesia/intubation, n (%)
8/26 (31%)
  Procedure time (skin to skin), mean ±SD, mins
114 ± 27
  Procedure time (skin to skin), median (IQR), mins
114 (90-138)
  Fluoroscopy, mean ±SD, mins
6 ±3
  Dose area product, mean ±SD, cGy × cm2
10 ±12
  Mapping points, mean ±SD
9449 ± 7784
  Focal PFA as ablation modality, n (%)
6/26 (23%)
  AT as predominant arrhythmia recurrence, n (%)
9/26 (35%)
Ablation strategy
  Re-isolation of pulmonary veins only
7/26 (23%)
  Left atrial posterior wall isolation only
5/26 (19%)
  Re-isolation of PV and left atrial posterior wall isolation
3/26 (12%)
  Other combinations of above including CTI-B, MIB, and FAT-A
11/26 (42%)
  Major complications
0/26 (0%)
DAP dose area product, IQR interquartile range, SD standard deviation, PFA pulsed field ablation, PVI pulmonary vein isolation, HD high density, AT atrial tachycardia, CTI-B cavotricuspid isthmus block, MIB mitral isthmus block, FAT-A focal atrial tachycardia ablation

3.2 Durability and reconnection patterns

The overall PVI durability per patient with four isolated veins was 11/26 (42%) (Table 3). The total number of durably isolated veins was 72/104 (69%). There was a numerical, but statistically insignificant, higher reconduction rate in the right-sided veins with reconduction rates of 35%, 42%, 27%, and 19% for right superior, right inferior, left superior, and left inferior, respectively (p=0.31) (Fig. 1). Likewise, there was a numerical, but statistically insignificant, higher rate of ipsilateral reconnection in the right-sided veins (31%) compared to the left-sided veins (15%) (p=0.32). The total number of reconnected veins was 32/104 (31%), averaging 1.2 ±1.3 per patient (all patients), and 2.1 ±1.1 for the patients with any reconnection. There was no significant difference in reconnection patterns for the PVs comparing use of 3D HD mapping post-PVI versus fluoroscopy-only based approach in the index procedure (Fig. 2). The total number of recorded reconnection gaps was 43 among the 15 patients with reconnections, averaging 1.7 ±1.8 per patient (all 26 patients) or 2.9 ± 1.4 for those 15 with any gap recorded. The gaps were significantly, and mostly clustered in the right-sided anterior carina regions with 15/43 (35%) gaps in regions 14 and 15 of the 16-segment PV model (P=0.009) (Fig. 3). Two examples of uHDx maps with anterior right-sided PV anterior reconnections in segments 14 and 15 are shown in Fig. 4. An example of an uHDx map with local activation time annotation showing an infero-posterior gap to the right-sided veins via segment 12 is shown in Fig. 5.
Table 3
Pulmonary vein reconnection and lesion durability data
Vein
Reconnection per patient
Vein
Reconnection per PV
Any vein
15/26 (58%)
Right superior
9/26 (35%)
1 vein
5/26 (19%)
Right inferior
11/26 (42%)
2 veins
5/26 (19%)
Left superior
7/26 (27%)
3 veins
3/26 (12%)
Left inferior
5/26 (19%)
4 veins
2/26 (8%)
Any right
12/52 (23%)
 
Any left
8/52 (15%)
Durability
  
Overall durability (all 4 veins isolated)
11/26 (42%)
Ipsilateral reconnection right
8/26 (31%)
Number of isolated veins
72/104 (69%)
Ipsilateral reconnection left
4/26 (15%)
PV pulmonary vein
Among the 12 patients with any right-sided PV reconnection, five (42%) of those had been treated with more PFA applications to the right-sided veins than standard protocol (mean additional PFA applications 3.2 ± 1.1).

3.3 Arrhythmia recurrences and mechanisms

The mean time from first procedure to recurrence (excluding blanking) was 179 ± 75 days and the clinical predominant recurrent arrhythmia mechanism was AF in 17/26 (65%) patients and regular atrial tachycardia (AT) in 9/26 (35%) (P=0.023). Of the nine regular ATs, there was no consistent pattern; three were found to be inducible roof-dependent flutters, two were inducible perimitral flutters, one focal AT from the nadir inferior LAPW in proximity to intact LAPWi line, and one from vena cava superior. Finally, two were classified as unidentified but suspected non-inducible perimitral flutters based an anterior scar location and slowing of conduction vectors in LA. Interestingly, in 7/9 of the patients with clinical predominant ATs the PVs were durably isolated and in all four of the perimitral flutters anterior scar substrate was present. The three roof-dependent flutters all had a narrow LAPW zone of viable myocardium and all these three index cases had been performed in fluoroscopy-only.

4 Discussion

This report describes the procedural and electrophysiological findings from clinically indicated repeat procedure after single-shot PFA. The main findings were [1] a lower durability and higher than expected rate of reconnected veins. [2] A high number of gaps at the anterior aspect of the right-sided pulmonary veins. [3] Clinical recurrent arrhythmia was predominantly AF. Only very limited data on clinically indicated repeat procedure after single-shot PFA is currently available.

4.1 Isolation at index procedure versus durability

Because we performed HD bipolar voltage maps in 58% of the index procedures with or without additional PFA applications, we are confident that these patients did not experience acute reconnections. Information on rates of acute reconnection after single-shot PFA is limited. Gunawardene et al. and Lemoine et al. reported acute reconnection in approximately 6% of the cases [21, 22], while we found that up to 20% needed additional PFA applications after post-PVI HD bipolar voltage map evaluation for PVI for a complete and satisfactory antral isolation of the PVs and ostia [15]. An association with better outcomes after wide antral circumferential lesions after PVI has been described and is selectively targeted when using point-by-point ablation [23]. The adapted current procedural work-flow of index single-shot PFA is to assess acute isolation and bidirectional block with the catheter in a basket formation in the veins without waiting time. Potentially, many operator–patient variations limits a thorough detailed mapping with the Farawave catheter to assess for acute reconduction in the minutes after successful “single-shot” isolation. This could lead to lower long-term durability rates.

4.2 Durability

It is well established that PV reconnection or low durability associates with increased recurrences and lower clinical efficacy [1, 24]. The rate of PV reconnection is naturally very different and much higher in a cohort of clinically indicated repeat procedures compared to mandated and protocol repeat procedures because of the population selection. This has been shown for RFA and cryo-balloon where mandated repeat procedures showed durability of 74–93% for RFA and 73–91% for cryo-balloon [1, 2528] while clinically indicated repeat procedures showed lower durability of 46–62% for RFA and 53–64% for cryo-balloon from the FIRE and ICE and CIRCA-DOSE trials and by following the CLOSE protocol [2931]. For multispline PFA, the only mandated repeat durability procedure published was the early works from Reddy et al. in the PFA waveform optimization preclinical studies of IMPULSE and PEFCAT [6]. Here, they showed an outstanding 96% PV durability in the optimized PFA waveform cohort. This phenomenal and promising durability has, however, not yet resulted in very low clinical recurrences. The 1-year outcomes of the industry-sponsored and independent single- and multicenter PFA registries are now available and show a 1-year recurrence-free rate of 60–75% for persistent AF and 70–90% for paroxysmal AF [5, 7, 8, 10, 11, 22] which are comparable to recurrence-free rates of recent RFA and cryo-balloon studies [32, 33]. Recurrence rates are, however, inherently difficult to compare and vary a lot study-to-study because of different follow-up methodology and monitoring employment. It is important to assess whether these clinical recurrence rates are related to failure of the electroporation to yield durable PVI or if recurrences are despite a complete durable PVI or even associated with increased man-made ATs in relation to the electroporation lesion set in the LA. Since PFA has only been commercially available for PVI since early 2021, now recurrences and clinically indicated procedures begin to show. The only available data on repeat procedures is the study from Frankfurt investigating 25 patients [14]. They found a PV reconnection rate of 9.1% (90.9% durability) and a predominance of ATs (64%) of which half were LAPW dependent ATs. They speculate that the many LAPW dependent ATs were associated with the lesion set unintentionally leaving a critical isthmus at the LAPW or roof segment. Since we used HD bipolar voltage maps after PVI in the 58% first cases, these (if observed) narrow isthmuses were typically treated with supplementary LAPWi. In the three cases of LAPW or roof-dependent flutter, we observed in our repeat procedures the index procedures had all been done in fluoroscopy-guidance only. This supports the findings from Frankfurt that this mechanism is a potential problematic issue in fluoroscopy-only single-shot PFA procedures. Integration of 3D-mapping in the PFA system would allow for preventive elimination of such a potential isthmus, if seen, by applying a PFA LAPWi. Our main finding of a much lower durability of 42% and rate of isolated veins of 69% compared to Frankfurt may to some degree relate to patient characteristics (paroxysmal AF in 76% versus our 35%) and selection for a repeat procedure (time to repeat ≈180 days versus our 292 days), favoring recognition of the early very symptomatic ATs (where we found durable PVI in 7/9 cases) in comparison to AF. This PFA PVI durability is in the range of the reported durability rates of RFA and cryo-balloon thermal technologies. This is a surprising and disappointing result considering the preclinical durability data and the results from Tohoku et al. On the other hand, we found a good durability in the few LAPWi included in the present cohort. We speculate that this overall finding is a combination of implementation phase, insufficient contact, and inadequate number/dosing of PFA applications.

4.3 Reconnection patterns

Numerically, the right-sided veins accounted for the most reconnected veins and gap identification showed that the anterior carina region of the right PVs had significantly more gaps than the other regions. We observed reconnections to all four of the veins and almost all the different 16 regions of the LA-PV models had electrically conducted gaps. This pattern, and in particular reconnections to the right inferior has been shown in RFA and cryo-balloon reports [20]. We speculate that this gap pattern relate to a [1] higher degree of PFA catheter displacement in the right PVs because of forceful contractions of the diaphragm; [2] an anatomy-based tendency of the catheter to orient posteriorly due to the transeptal orientation; )3) anatomical difficulties, reduced maneuvrability, and tissue contact in aligning the catheter in the right inferior PV; [4] inadequate PFA application dosing; and [5] finally the right inferior is commonly the last vein to be isolated leaving no time to observe the acute reconnection as we have previously described in a post-PFA PVI mapping study [15].

4.4 Limitations

This is a single-center study with limited sample size. No long-term follow-up is available after the repeat procedure. The indication criteria for repeat ablation were not uniform and were based on a case-to-case scenario. All patients with PFA as index procedure were considered; thus, the results include the very early experiences and implementation phases of PFA at our center. Results should be interpreted in the light of the above.

5 Conclusion

Durable PVI was observed in 42% of the patients at time of repeat ablation after single-shot PFA PVI. No significant difference in PV reconnection pattern was observed, but the gap location was preferentially located at the anterior aspects of the right-sided PVs. The predominant recurrence arrhythmia was AF. More data is warranted to understand lesion formation, durability, and AT circuits after PFA.

Declarations

Ethics approval

This research study was conducted retrospectively from data obtained for clinical purposes utilizing anonymized data approved by Herlev-Gentofte University Hospital Institutional Review Board (Case Number:22035743).

Conflict of interest

MHR, AJ, MLH, and MH has nothing to disclose. RW has received research grants and speaker honoraria from Biosense Webster not related to the present work and JH has received grants, speaker honoraria, and consultant fees from Biosense Webster and speaker honoraria and consultant fees from Boston Scientific. SK has received research grants from Biosense Webster not related to the present work.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Sorensen SK, Johannessen A, Worck R, Hansen ML, Hansen J. Radiofrequency versus cryoballoon catheter ablation for paroxysmal atrial fibrillation: durability of pulmonary vein isolation and effect on atrial fibrillation burden: the RACE-AF randomized controlled trial. Circ Arrhythm Electrophysiol. 2021;14(5):e009573.CrossRefPubMedPubMedCentral Sorensen SK, Johannessen A, Worck R, Hansen ML, Hansen J. Radiofrequency versus cryoballoon catheter ablation for paroxysmal atrial fibrillation: durability of pulmonary vein isolation and effect on atrial fibrillation burden: the RACE-AF randomized controlled trial. Circ Arrhythm Electrophysiol. 2021;14(5):e009573.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Neven K, Futing A, Byrd I, Heil RW Jr, Fish JM, Feeney DA, et al. Absence of (sub-)acute cerebral events or lesions after electroporation ablation in the left-sided canine heart. Heart Rhythm. 2021;18(6):1004–11.CrossRefPubMed Neven K, Futing A, Byrd I, Heil RW Jr, Fish JM, Feeney DA, et al. Absence of (sub-)acute cerebral events or lesions after electroporation ablation in the left-sided canine heart. Heart Rhythm. 2021;18(6):1004–11.CrossRefPubMed
4.
Zurück zum Zitat Koruth JS, Kuroki K, Kawamura I, Brose R, Viswanathan R, Buck ED, et al. Pulsed field ablation versus radiofrequency ablation: esophageal injury in a novel porcine model. Circ Arrhythm Electrophysiol. 2020;13(3):e008303.CrossRefPubMedPubMedCentral Koruth JS, Kuroki K, Kawamura I, Brose R, Viswanathan R, Buck ED, et al. Pulsed field ablation versus radiofrequency ablation: esophageal injury in a novel porcine model. Circ Arrhythm Electrophysiol. 2020;13(3):e008303.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7(5):614–27.CrossRefPubMed Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7(5):614–27.CrossRefPubMed
6.
Zurück zum Zitat Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019;74(3):315–26.CrossRefPubMed Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019;74(3):315–26.CrossRefPubMed
7.
Zurück zum Zitat Reddy VY, Anic A, Koruth J, Petru J, Funasako M, Minami K, et al. Pulsed field ablation in patients with persistent atrial fibrillation. J Am Coll Cardiol. 2020;76(9):1068–80.CrossRefPubMed Reddy VY, Anic A, Koruth J, Petru J, Funasako M, Minami K, et al. Pulsed field ablation in patients with persistent atrial fibrillation. J Am Coll Cardiol. 2020;76(9):1068–80.CrossRefPubMed
9.
Zurück zum Zitat Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace. 2022;24(8):1256–66.CrossRefPubMedPubMedCentral Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace. 2022;24(8):1256–66.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Schmidt B, Bordignon S, Tohoku S, Chen S, Bologna F, Urbanek L, et al. 5S study: safe and simple single shot pulmonary vein isolation with pulsed field ablation using sedation. Circ Arrhythm Electrophysiol. 2022;15(6):e010817.CrossRefPubMed Schmidt B, Bordignon S, Tohoku S, Chen S, Bologna F, Urbanek L, et al. 5S study: safe and simple single shot pulmonary vein isolation with pulsed field ablation using sedation. Circ Arrhythm Electrophysiol. 2022;15(6):e010817.CrossRefPubMed
12.
Zurück zum Zitat Magni FT, Mulder BA, Groenveld HF, Wiesfeld ACP, Tieleman RG, Cox MG, et al. Initial experience with pulsed field ablation for atrial fibrillation. Front Cardiovasc Med. 2022;9:959186.CrossRefPubMedPubMedCentral Magni FT, Mulder BA, Groenveld HF, Wiesfeld ACP, Tieleman RG, Cox MG, et al. Initial experience with pulsed field ablation for atrial fibrillation. Front Cardiovasc Med. 2022;9:959186.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Futing A, Reinsch N, Howel D, Brokkaar L, Rahe G, Neven K. First experience with pulsed field ablation as routine treatment for paroxysmal atrial fibrillation. Europace. 2022;24(7):1084–92.CrossRefPubMed Futing A, Reinsch N, Howel D, Brokkaar L, Rahe G, Neven K. First experience with pulsed field ablation as routine treatment for paroxysmal atrial fibrillation. Europace. 2022;24(7):1084–92.CrossRefPubMed
14.
Zurück zum Zitat Tohoku S, Chun KRJ, Bordignon S, Chen S, Schaack D, Urbanek L, et al. Findings from repeat ablation using high-density mapping after pulmonary vein isolation with pulsed field ablation. Europace. 2023;25(2):433–40.CrossRefPubMed Tohoku S, Chun KRJ, Bordignon S, Chen S, Schaack D, Urbanek L, et al. Findings from repeat ablation using high-density mapping after pulmonary vein isolation with pulsed field ablation. Europace. 2023;25(2):433–40.CrossRefPubMed
15.
Zurück zum Zitat Ruwald MH, Johannessen A, Hansen ML, Haugdal M, Worck R, Hansen J. Utility of high-density 3D-bipolar voltage map after pulmonary vein isolation by pulsed-field ablation. JACC Clin Electrophysiol. 2023;9(4):588–90.CrossRefPubMed Ruwald MH, Johannessen A, Hansen ML, Haugdal M, Worck R, Hansen J. Utility of high-density 3D-bipolar voltage map after pulmonary vein isolation by pulsed-field ablation. JACC Clin Electrophysiol. 2023;9(4):588–90.CrossRefPubMed
16.
Zurück zum Zitat Vicera JJB, Lin YJ, Lee PT, Chang SL, Lo LW, Hu YF, et al. Identification of critical isthmus using coherent mapping in patients with scar-related atrial tachycardia. J Cardiovasc Electrophysiol. 2020;31(6):1436–47.CrossRefPubMedPubMedCentral Vicera JJB, Lin YJ, Lee PT, Chang SL, Lo LW, Hu YF, et al. Identification of critical isthmus using coherent mapping in patients with scar-related atrial tachycardia. J Cardiovasc Electrophysiol. 2020;31(6):1436–47.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Ruwald MH, Johannessen A, Hansen ML, Worck R, Hansen J. Pulsed field ablation of the cavotricuspid isthmus using a multispline-electrode pulsed field ablation catheter. HeartRhythm Case Rep. 2022;8(3):147–50.CrossRefPubMed Ruwald MH, Johannessen A, Hansen ML, Worck R, Hansen J. Pulsed field ablation of the cavotricuspid isthmus using a multispline-electrode pulsed field ablation catheter. HeartRhythm Case Rep. 2022;8(3):147–50.CrossRefPubMed
18.
Zurück zum Zitat Duytschaever M, De Pooter J, Demolder A, El Haddad M, Phlips T, Strisciuglio T, et al. Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: the CLOSE to CURE study. Heart Rhythm. 2020;17(4):535–43.CrossRefPubMed Duytschaever M, De Pooter J, Demolder A, El Haddad M, Phlips T, Strisciuglio T, et al. Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: the CLOSE to CURE study. Heart Rhythm. 2020;17(4):535–43.CrossRefPubMed
20.
Zurück zum Zitat Sorensen SK, Johannessen A, Worck R, Hansen ML, Ruwald MH, Hansen J. Differential gap location after radiofrequency versus cryoballoon pulmonary vein isolation: insights from a randomized trial with protocol-mandated repeat procedure. J Cardiovasc Electrophysiol. 2023;34(3):519–26.CrossRefPubMed Sorensen SK, Johannessen A, Worck R, Hansen ML, Ruwald MH, Hansen J. Differential gap location after radiofrequency versus cryoballoon pulmonary vein isolation: insights from a randomized trial with protocol-mandated repeat procedure. J Cardiovasc Electrophysiol. 2023;34(3):519–26.CrossRefPubMed
21.
Zurück zum Zitat Gunawardene MA, Schaeffer BN, Jularic M, Eickholt C, Maurer T, Akbulak RO, et al. Pulsed-field ablation combined with ultrahigh-density mapping in patients undergoing catheter ablation for atrial fibrillation: practical and electrophysiological considerations. J Cardiovasc Electrophysiol. 2022;33(3):345–56.CrossRefPubMed Gunawardene MA, Schaeffer BN, Jularic M, Eickholt C, Maurer T, Akbulak RO, et al. Pulsed-field ablation combined with ultrahigh-density mapping in patients undergoing catheter ablation for atrial fibrillation: practical and electrophysiological considerations. J Cardiovasc Electrophysiol. 2022;33(3):345–56.CrossRefPubMed
22.
Zurück zum Zitat Lemoine MD, Fink T, Mencke C, Schleberger R, My I, Obergassel J, et al. Pulsed-field ablation-based pulmonary vein isolation: acute safety, efficacy and short-term follow-up in a multi-center real world scenario. Clin Res Cardiol. 2022; https://doi.org/10.1007/s00392-022-02091-2. Lemoine MD, Fink T, Mencke C, Schleberger R, My I, Obergassel J, et al. Pulsed-field ablation-based pulmonary vein isolation: acute safety, efficacy and short-term follow-up in a multi-center real world scenario. Clin Res Cardiol. 2022; https://​doi.​org/​10.​1007/​s00392-022-02091-2.
23.
Zurück zum Zitat Kiuchi K, Kircher S, Watanabe N, Gaspar T, Rolf S, Arya A, et al. Quantitative analysis of isolation area and rhythm outcome in patients with paroxysmal atrial fibrillation after circumferential pulmonary vein antrum isolation using the pace-and-ablate technique. Circ Arrhythm Electrophysiol. 2012;5(4):667–75.CrossRefPubMed Kiuchi K, Kircher S, Watanabe N, Gaspar T, Rolf S, Arya A, et al. Quantitative analysis of isolation area and rhythm outcome in patients with paroxysmal atrial fibrillation after circumferential pulmonary vein antrum isolation using the pace-and-ablate technique. Circ Arrhythm Electrophysiol. 2012;5(4):667–75.CrossRefPubMed
24.
Zurück zum Zitat Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger FT, et al. Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation. 2005;111(2):127–35.CrossRefPubMed Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger FT, et al. Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation. 2005;111(2):127–35.CrossRefPubMed
25.
Zurück zum Zitat Hussein A, Das M, Riva S, Morgan M, Ronayne C, Sahni A, et al. Use of ablation index-guided ablation results in high rates of durable pulmonary vein isolation and freedom from arrhythmia in persistent atrial fibrillation patients: the PRAISE study results. Circ Arrhythm Electrophysiol. 2018;11(9):e006576.CrossRefPubMed Hussein A, Das M, Riva S, Morgan M, Ronayne C, Sahni A, et al. Use of ablation index-guided ablation results in high rates of durable pulmonary vein isolation and freedom from arrhythmia in persistent atrial fibrillation patients: the PRAISE study results. Circ Arrhythm Electrophysiol. 2018;11(9):e006576.CrossRefPubMed
26.
Zurück zum Zitat Das M, Wynn GJ, Saeed Y, Gomes S, Morgan M, Ronayne C, et al. Pulmonary vein re-isolation as a routine strategy regardless of symptoms: the PRESSURE randomized controlled trial. JACC Clin Electrophysiol. 2017;3(6):602–11.CrossRefPubMed Das M, Wynn GJ, Saeed Y, Gomes S, Morgan M, Ronayne C, et al. Pulmonary vein re-isolation as a routine strategy regardless of symptoms: the PRESSURE randomized controlled trial. JACC Clin Electrophysiol. 2017;3(6):602–11.CrossRefPubMed
27.
Zurück zum Zitat Miyazaki S, Taniguchi H, Hachiya H, Nakamura H, Takagi T, Iwasawa J, et al. Quantitative analysis of the isolation area during the chronic phase after a 28-mm second-generation cryoballoon ablation demarcated by high-resolution electroanatomic mapping. Circ Arrhythm Electrophysiol. 2016;9(5):e003879.CrossRefPubMed Miyazaki S, Taniguchi H, Hachiya H, Nakamura H, Takagi T, Iwasawa J, et al. Quantitative analysis of the isolation area during the chronic phase after a 28-mm second-generation cryoballoon ablation demarcated by high-resolution electroanatomic mapping. Circ Arrhythm Electrophysiol. 2016;9(5):e003879.CrossRefPubMed
28.
Zurück zum Zitat Reddy VY, Sediva L, Petru J, Skoda J, Chovanec M, Chitovova Z, et al. Durability of pulmonary vein isolation with cryoballoon ablation: results from the Sustained PV Isolation with Arctic Front Advance (SUPIR) study. J Cardiovasc Electrophysiol. 2015;26(5):493–500.CrossRefPubMed Reddy VY, Sediva L, Petru J, Skoda J, Chovanec M, Chitovova Z, et al. Durability of pulmonary vein isolation with cryoballoon ablation: results from the Sustained PV Isolation with Arctic Front Advance (SUPIR) study. J Cardiovasc Electrophysiol. 2015;26(5):493–500.CrossRefPubMed
29.
Zurück zum Zitat Kuck KH, Albenque JP, Chun KJ, Furnkranz A, Busch M, Elvan A, et al. Repeat ablation for atrial fibrillation recurrence post cryoballoon or radiofrequency ablation in the FIRE AND ICE trial. Circ Arrhythm Electrophysiol. 2019;12(6):e007247.CrossRefPubMed Kuck KH, Albenque JP, Chun KJ, Furnkranz A, Busch M, Elvan A, et al. Repeat ablation for atrial fibrillation recurrence post cryoballoon or radiofrequency ablation in the FIRE AND ICE trial. Circ Arrhythm Electrophysiol. 2019;12(6):e007247.CrossRefPubMed
30.
Zurück zum Zitat Cheung CC, Deyell MW, Macle L, Verma A, Champagne J, Leong-Sit P, et al. Repeat atrial fibrillation ablation procedures in the CIRCA-DOSE study. Circ Arrhythm Electrophysiol. 2020;13(9):e008480.CrossRefPubMed Cheung CC, Deyell MW, Macle L, Verma A, Champagne J, Leong-Sit P, et al. Repeat atrial fibrillation ablation procedures in the CIRCA-DOSE study. Circ Arrhythm Electrophysiol. 2020;13(9):e008480.CrossRefPubMed
31.
Zurück zum Zitat De Pooter J, Strisciuglio T, El Haddad M, Wolf M, Phlips T, Vandekerckhove Y, et al. Pulmonary vein reconnection no longer occurs in the majority of patients after a single pulmonary vein isolation procedure. JACC Clin Electrophysiol. 2019;5(3):295–305.CrossRefPubMed De Pooter J, Strisciuglio T, El Haddad M, Wolf M, Phlips T, Vandekerckhove Y, et al. Pulmonary vein reconnection no longer occurs in the majority of patients after a single pulmonary vein isolation procedure. JACC Clin Electrophysiol. 2019;5(3):295–305.CrossRefPubMed
32.
Zurück zum Zitat Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation. 2019;140(22):1779–88.CrossRefPubMed Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation. 2019;140(22):1779–88.CrossRefPubMed
33.
Zurück zum Zitat Andrade JG, Deyell MW, Verma A, Macle L, Khairy P. The cryoballoon vs irrigated radiofrequency catheter ablation (CIRCA-DOSE) study results in context. Arrhythmia Electrophysiol Rev. 2020;9(1):34–9.CrossRef Andrade JG, Deyell MW, Verma A, Macle L, Khairy P. The cryoballoon vs irrigated radiofrequency catheter ablation (CIRCA-DOSE) study results in context. Arrhythmia Electrophysiol Rev. 2020;9(1):34–9.CrossRef
Metadaten
Titel
Characterization of durability and reconnection patterns at time of repeat ablation after single-shot pulsed field pulmonary vein isolation
verfasst von
Martin H. Ruwald
Martin Haugdal
Rene Worck
Arne Johannessen
Morten Lock Hansen
Samuel K. Sørensen
Jim Hansen
Publikationsdatum
30.09.2023
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 2/2024
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-023-01655-0

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Kardiologie

Kaffeegenuss sicher bei Vorhofflimmern

Menschen mit Vorhofflimmern fürchten oft, Kaffee könnte schlecht für ihr Herz sein. Solche Ängste sind offenbar unbegründet: Zwei Schweizer Untersuchungen deuten sogar auf eine reduzierte Rate von kardiovaskulären Ereignissen unter Kaffeetrinkern.

Mit jedem Defibrillationsversuch sinkt die Überlebenschance

Wie wirkt es sich auf die Prognose aus, wenn bei Herzstillstand einmal, zweimal oder gar 29 Mal geschockt werden muss? Laut einer aktuellen Studie besteht ein deutlicher Zusammenhang zwischen der Zahl der Defibrillationsversuche und den Überlebenschancen.

Mit Spenderherz von Triathlon zu Triathlon

Ein 50-Jähriger mit Spenderherz rennt, radelt und schwimmt bis zu 14 Stunden in der Woche – beim Hawaii-Triathlon erreicht er einen Platz im Mittelfeld. Sein neues Herz kann sich an die Belastung erstaunlich gut anpassen. Selbst mit 65 Jahren ist er noch ungewöhnlich fit.

Kein Unterschied bei inadäquaten Schocks zwischen ICD-Typen

Inadäquate Schockabgaben sind ein unerwünschter Effekt der Therapie mit implantierbaren Kardioverter-Defibrillatoren. Subkutanen Geräten haftet dabei der Ruf an, dafür besonders anfällig zu sein. Die PRAETORIAN-Forschungsgruppe ist dem nachgegangen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.